Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction (STRIDERCan)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02442492 |
Recruitment Status :
Terminated
(Trial terminated following Dutch DSMB recommendation for their Study)
First Posted : May 13, 2015
Last Update Posted : February 11, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Intrauterine Growth Restriction (IUGR) Fetal Growth Restriction (FGR) | Drug: Sildenafil Drug: Placebo | Phase 2 Phase 3 |
STRIDER Canada is one of a consortium of STRIDER randomised controlled trials (RCTs) each of which is designed to determine whether or not maternal treatment with oral sildenafil citrate improves perinatal outcomes in pregnancies complicated by EO IUGR without increasing risks to the mother.
STRIDER Canada is designed as investigator-initiated double-blind, randomised placebo-controlled trial of 90 women with a diagnosis of early-onset intrauterine growth restriction with an intention-to-treat analysis. 90 Women with affected pregnancies will be recruited and randomised to receive either sildenafil or placebo.
Women reviewed in the participating fetal medicine with a diagnosis of a pregnancy affected by early-onset IUGR between 18+0 and 27+6 weeks of gestation and serum PlGF levels less than 5th percentile for gestational age will be considered for randomisation. In Canadian STRIDER, the treatment with either sildenafil or placebo (25 mg 3 times per day) will be applied from the time of randomisation until delivery, or up to 31+6 weeks of gestation whichever comes first.
All patients randomly assigned to one of the treatments will be analysed together, regardless of whether or not they completed or received that treatment, on an intention to treat basis.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 21 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | STRIDER Canada: A Randomized Controlled Trial of Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction (Canada) |
Actual Study Start Date : | January 2017 |
Actual Primary Completion Date : | July 2018 |
Actual Study Completion Date : | April 2019 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Sildenafil
Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
|
Drug: Sildenafil
Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner. |
Placebo Comparator: Placebo
Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
|
Drug: Placebo
Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner. |
- compare the gestational age at delivery (d) between sildenafil- and placebo-treated groups [ Time Frame: 6 weeks after postpartum ]
- live birth [ Time Frame: at delivery if alive ]
- survival to hospital discharge [ Time Frame: measured at the final hospital discharge (average upto 6 weeks postpartum) ]
- intact survival (defined as survival to estimated due date (EDD) without evidence of severe central nervous system [CNS] injury [by ultrasound and/or magnetic resonance imaging (MRI)]) [ Time Frame: measured at estimated due date (EDD) ]
- composite non-CNS (Central Nervous System) severe morbidity (one/more of bronchopulmonary dysplasia requiring supplemental oxygen on hospital discharge, ≥grade 3 retinopathy of prematurity, or necrotising enterocolitis) [ Time Frame: up to 6 weeks after postpartum or final discharge which ever is sooner ]
- Maternal - symptomatic hypotension [ Time Frame: up to 6 weeks after postpartum or final discharge which ever is sooner ]
- Maternal - pre-eclampsia [ Time Frame: from randomisation to delivery (expected to be assessed weekly) ]
- Maternal - mode of delivery [ Time Frame: At delivery ]
- Maternal - haemorrhage requiring transfusion [ Time Frame: At delivery ]
- Maternal - maternal plasma PlGF. [ Time Frame: from randomisation to delivery (expected to be assessed weekly) ]
- Maternal - uterine artery Doppler indices [ Time Frame: from randomisation to delivery (expected to be done weekly) ]
- Perinatal - fetal growth velocity [ Time Frame: from randomisation to delivery (expected to be done weekly) ]
- Perinatal - fetal Doppler [ Time Frame: from randomisation to delivery (expected to be done weekly) ]
- Perinatal - amniotic fluid [ Time Frame: At randomisation, if done ]
- Perinatal - fetal heart indices [ Time Frame: rom randomisation to delivery (expected to be done weekly) ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Gestational age from 18+0 - 27+6 weeks
AND
-
EO IUGR, defined as
-
ultrasound (U/S) measurement of the fetal abdominal circumference (AC) <10th percentile for gestational age and/or documented reduced fetal growth velocity complicating either a prior EO IUGR with adverse perinatal outcome or abnormal uterine artery waveform in the index pregnancy;
OR
- U/S estimate of fetal weight (EFW) <700g
-
AND
- Serum PlGF < 5th percentile for gestational age
Exclusion Criteria:
- known fetal aneuploidy
- known fetal anomaly/syndrome/congenital infection confirmed at the time of enrolment
- decision made to terminate pregnancy
- current cocaine or vasoconstrictor use (e.g. crystal meth) (risk of acute cardiac events)
- contraindication to sildenafil therapy, e.g. known significant maternal cardiac disease, left ventricular outflow tract obstruction, concomitant treatment with nitrates or previous allergy to sildenafil
- known HIV positive status (due drug-drug interaction between sildenafil and antiretrovirals)
- receiving peripheral alpha-blockers (e.g. prazosin)
- prior participation in a STRIDER trials
- pre-eclampsia or gestational hypertension diagnosed

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02442492
Canada, Alberta | |
Royal Alexandra Hospital | |
Edmonton, Alberta, Canada, T5H 3V9 | |
Canada, British Columbia | |
BC Women's Hospital/University of British Columbia | |
Vancouver, British Columbia, Canada, V7H3N1 | |
Canada, Ontario | |
London Health Sciences Centre | |
London, Ontario, Canada, N6A 5W9 | |
Canada, Quebec | |
CHU Sainte-Justine | |
Montréal, Quebec, Canada, H3T 1C5 | |
CHU de Quebec - Universite Laval | |
Quebec City, Quebec, Canada, G2N 0B2 |
Principal Investigator: | Peter von Dadelszen, BMedSc, MBChB, DipObst, DPhil, | University of British Columbia | |
Principal Investigator: | Kenneth Lim, MD FRCSC | University of British Columbia |
Responsible Party: | Kenneth Lim, Study Principal Investigator, University of British Columbia |
ClinicalTrials.gov Identifier: | NCT02442492 |
Other Study ID Numbers: |
H15-00899 |
First Posted: | May 13, 2015 Key Record Dates |
Last Update Posted: | February 11, 2020 |
Last Verified: | February 2020 |
sildenafil IUGR FGR STRIDER |
Fetal Growth Retardation Fetal Diseases Pregnancy Complications Growth Disorders Pathologic Processes Sildenafil Citrate |
Vasodilator Agents Phosphodiesterase 5 Inhibitors Phosphodiesterase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Urological Agents |